Nytt og fint format på årsrapporten:
2021 has been described as ‘a year to forget’ for the biotechnology industry. The world was exhausted from the pandemic. The financial market was challenging. For the Ultimovacs team, despite working from our home offices most of the time, 2021 was a year to remember.
Ultimovacs’ mission is to extend and improve the life of patients by directing the immune system against the core of cancer. 2021 was the year we celebrated the 10-year anniversary for our company. Our lead product, UV1, is based on decades of immunotherapy research and strong scientificresults from Oslo University Hospital, led by our Chief Scientific Officer, Gustav Gaudernack.
[…]
Ultimovacs continues to extend the boundaries of medicine in immuno-oncology, to provide treatments to an increasing number of patients who currently have limited therapeutic options. Our talented team based in Norway and Sweden now numbers 25 individuals from 7 nationalities. We will continue to perform novel research, explore new opportunities for the TET technology platform, prepare for Phase III and commercialization of UV1, and work continuously with the regulatory authorities. Our extensive Phase II clinical program across five cancer indications with severe unmet needs will enroll more than 650 patients at 100 clinics in 15 countries.
I am impressed by and proud of the ambitions, commitment, and professionalism in the Ultimovacs team, establishing a reputation as a leading and active player in immuno-oncology. 10 years of innovation and dedication have brought us here. We plan to continue to deliver and I look forward to another year of progress in our multiple projects.